Movement Alert｜Cigna Group Intraday Rise 3.01%, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees

Market Focus06-05

On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.

On the news front, Cigna announced it will stop covering GLP-1 weight loss medications — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound — in its employee health plan effective July 1. The market interpreted this move as a positive cost control signal.

The company stated that the decision was made as drug supply has increased and new alternatives have emerged, though coverage for Type 2 diabetes medications remains unaffected. As of last year-end, Cigna employed approximately 67,700 workers, with 88% based in the United States. The discontinuation of GLP-1 reimbursement is expected to significantly reduce employee medical plan expenditures, providing positive support to the company's profit margins. This announcement follows a broader trend among insurers reassessing coverage of costly GLP-1 drugs amid rising utilization rates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169763882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 23:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169763882","market":"us","top_or_hot":-1,"title":"Movement Alert｜Cigna Group Intraday Rise 3.01%, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees","media":"Market Focus","content":"<p><p>On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.</p><p>On the news front, Cigna announced it will stop covering GLP-1 weight loss medications — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound — in its employee health plan effective July 1. The market interpreted this move as a positive cost control signal.</p><p>The company stated that the decision was made as drug supply has increased and new alternatives have emerged, though coverage for Type 2 diabetes medications remains unaffected. As of last year-end, Cigna employed approximately 67,700 workers, with 88% based in the United States. The discontinuation of GLP-1 reimbursement is expected to significantly reduce employee medical plan expenditures, providing positive support to the company's profit margins. This announcement follows a broader trend among insurers reassessing coverage of costly GLP-1 drugs amid rising utilization rates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Cigna Group Intraday Rise 3.01%, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Cigna Group Intraday Rise 3.01%, Announces Discontinuation of GLP-1 Weight Loss Drug Reimbursement for Employees\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.</p><p>On the news front, Cigna announced it will stop covering GLP-1 weight loss medications — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound — in its employee health plan effective July 1. The market interpreted this move as a positive cost control signal.</p><p>The company stated that the decision was made as drug supply has increased and new alternatives have emerged, though coverage for Type 2 diabetes medications remains unaffected. As of last year-end, Cigna employed approximately 67,700 workers, with 88% based in the United States. The discontinuation of GLP-1 reimbursement is expected to significantly reduce employee medical plan expenditures, providing positive support to the company's profit margins. This announcement follows a broader trend among insurers reassessing coverage of costly GLP-1 drugs amid rising utilization rates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CI","symbol_name":"信诺保险","start_time":0,"source_url":"","article_id":"1169763882","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169763882","pubTimestamp":1780673351,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.On the news front, Cigna announced it will stop covering GLP-1 weight loss...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CI":"信诺保险"},"translate_title":"动静快讯|招商信诺集团盘中涨3.01%，宣布停止员工GLP-1减肥药报销","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1},"content_text":"On June 5, Cigna Group rose 3.01% in regular trading, trading at $289.13/share, with trading volume of $127 million.On the news front, Cigna announced it will stop covering GLP-1 weight loss medications — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound — in its employee health plan effective July 1. The market interpreted this move as a positive cost control signal.The company stated that the decision was made as drug supply has increased and new alternatives have emerged, though coverage for Type 2 diabetes medications remains unaffected. As of last year-end, Cigna employed approximately 67,700 workers, with 88% based in the United States. The discontinuation of GLP-1 reimbursement is expected to significantly reduce employee medical plan expenditures, providing positive support to the company's profit margins. This announcement follows a broader trend among insurers reassessing coverage of costly GLP-1 drugs amid rising utilization rates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169763882","isCrawlerRequest":true}